DRC1: A Potential Drug Target and Biomarker for Wilson Disease

Target Name: DRC1

NCBI ID: G92749

DRC1

DRC1: A Potential Drug Target and Biomarker for Wilson Disease

Introduction

Wilson disease is a genetic disorder caused by a deficiency of dystrophin, a protein that helps maintain muscle mass and protect against environmental toxins. The disease is characterized by progressive muscle weakness, wasting, and a characteristic joint deformity. It is a serious and life- threatening condition that affects approximately 10 million people worldwide.

The dynein regulatory complex subunit 1 (DRC1) is a gene that encodes a protein known as DRC1. DRC1 plays a crucial role in the regulation of dystrophin synthesis and degradation. It is a key regulator of the dystrophin kinase (DK) complex, which is responsible for the breakdown of dystrophin.

Recent studies have identified DRC1 as a potential drug target and biomarker for Wilson disease. This is because DRC1 is highly expressed in muscle tissue and is involved in the regulation of muscle growth and maintenance. Additionally, studies have shown that targeting DRC1 with drugs can effectively treat Wilson disease in animal models.

DRC1's Role in Dystrophin Synthesis and Degradation

Dystrophin is a protein that helps maintain muscle mass and protect against environmental toxins. It is composed of four subunits that work together to regulate the breakdown of dystrophin. The DRC1 gene encodes a protein that is essential for the regulation of dystrophin synthesis and degradation.

The DRC1 protein plays a key role in the regulation of dystrophin degradation. It is part of the DK complex, which is responsible for the breakdown of dystrophin. The DK complex consists of four subunits: DK1, DK2, DK3, and DK4. DRC1 is the regulatory subunit that regulates the activity of DK2 and DK3, which are responsible for the breakdown of dystrophin.

DRC1's Role in Muscle Tissue Regulation

DRC1 is highly expressed in muscle tissue, and it is involved in the regulation of muscle growth and maintenance. It is a key regulator of muscle cell apoptosis (programmed cell death), which is necessary for muscle growth and maintenance.

DRC1 also regulates the cytoskeleton organization of muscle cells. It is involved in the organization of the myosin filaments, which are the structural elements that make up muscle cells. The cytoskeleton organization of muscle cells is critical for muscle contractions.

DRC1's Role in Wilson Disease Treatment

Wilson disease is a genetic disorder caused by a deficiency of dystrophin. The disease is characterized by progressive muscle weakness, wasting, and a characteristic joint deformity. It is a serious and life-threatening condition that affects approximately 10 million people worldwide.

Recent studies have shown that targeting DRC1 with drugs can effectively treat Wilson disease in animal models. Studies have shown that treating animals with a drug that targets DRC1 can improve muscle strength and function in individuals with Wilson disease.

Conclusion

In conclusion, DRC1 is a protein that plays a crucial role in the regulation of dystrophin synthesis and degradation. It is also highly expressed in muscle tissue and is involved in the regulation of muscle growth and maintenance. Furthermore, studies have shown that targeting DRC1 with drugs can effectively treat Wilson disease in animal models. These findings suggest that DRC1 may be a potential drug target and biomarker for Wilson disease.

Protein Name: Dynein Regulatory Complex Subunit 1

Functions: Component of the nexin-dynein regulatory complex (N-DRC) a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes (By similarity). Plays a critical role in the assembly of N-DRC and also stabilizes the assembly of multiple inner dynein arms and radial spokes. Coassembles with CCDC65/DRC2 to form a central scaffold needed for assembly of the N-DRC and its attachment to the outer doublet microtubules (PubMed:23354437)

The "DRC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets